CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 6, November/December 2011
302
AFRICA
References
1.
Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood
pressure-related disease, 2001.
Lancet
2008;
371
(9623): 1513–1518.
2.
Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers
A. Blood pressure and the global burden of disease 2000. Part II: esti-
mates of attributable burden.
J Hypertens
2006;
24
(3):
423–430.
3.
Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers
A. Blood pressure and the global burden of disease 2000. Part 1:
estimates of blood pressure levels.
J Hypertens
2006;
24
(3):
413–422.
4.
Cooper RS, Amoah AG, Mensah GA. High blood pressure: the founda-
tion for epidemic cardiovascular disease in African populations.
Ethn
Dis
2003;
13
(2 Suppl 2): S48–52.
5.
Addo J, Smeeth L, Leon DA. Hypertension in sub-Saharan Africa: a
systematic review.
Hypertension
2007;
50
(6): 1012–1018.
6.
Ekere AU, Yellowe BE, Umune S. Mortality patterns in the accident and
emergency department of an urban hospital in Nigeria.
Niger J Clin
Pract
2005;
8
(9):
14–18.
7.
Ogunniyi A, Baiyewu O, Gureje O,
et al
. Morbidity pattern in a sample
of elderly Nigerians resident in Idikan community, Ibadan.
West Afr J
Med
2001;
20
(4):
227–231.
8.
Okojie OH, Isah EC, Okoro E. Assessment of health of senior execu-
tives in a developing country.
Publ Hlth
2000;
114
(4):
273–275.
9.
Ogah OS. Hypertension in sub-SaharanAfrican populations: the burden
of hypertension in Nigeria.
Ethn Dis
2006;
16
(4): 765.
10. Chobanian AV, Bakris GL, Black HR,
et al
. The seventh report of the
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: the JNC 7 report.
J Am Med Assoc
2003;
289
(19):
2560–2572.
11. American Society of Hypertension. Recommendations for routine
blood pressure measurement by indirect cuff sphygmomanometer.
Am
J Hypertens Suppl
1992:
207–209.
12. Dubois D, Dubois EF. A formula to estimate the approximate surface
area if height and weight be known.
Arch Intern Med
1916;
17
:
863–871.
13. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regard-
ing quantitation in M-mode echocardiography. Results of a survey of
echocardiographic measurements.
Circulation
1978;
56
:
1072–1083.
14. Ogah OS, Adebanjo AT, Otukoya AS, Jagusa TJ. Echocardiography
in Nigeria: use, problems, reproducibility and potentials.
Cardiovasc
Ultrasound
2006;
4
: 13.
15. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocar-
diographic volume determinations: echocardiographic-angiographic
correlations in the presence of absence of asynergy.
Am J Cardiol
1976;
37
(1):
7–11.
16. Devereux RB, Reichek N. Echocardiographic determination of LVM in
man: anatomic validation of the method.
Circulation
1977;
5
: 613–618.
17. Devereux RB, Alonso DR, Lutas EM,
et al
. Echocardiographic assess-
ment of left ventricular hypertrophy:comparison to necropsy findings.
Am J Cardiol
1986;
57
:
450–458.
18. Palmieri V, Dahlof B, De Quattro V,
et al
. Reliability of echocar-
diographic assessment of left ventricular structure and function. The
PRESERVE study.
J Am Coll Cardiol
1999;
34
:
1625–1632.
19. Roman MJ. How best to identify prognostically important left ventricu-
lar hypertrophy.
J Am Coll Cardiol
1997;
29
:
648–650.
20. Hays AG, Sacco RL, Rundek T,
et al.
Left ventricular systolic dysfunc-
tion and the risk of ischemic stroke in a multiethnic population.
Stroke
2006;
37
(7):
1715–1719.
21. Devereux RB, Roman MJ, Paranicas M,
et al
. A population-based
assessment of left ventricular systolic dysfunction in middle-aged
and older adults: the Strong Heart study.
Am Heart J
2001;
141
(3):
439–446.
22. Devereux RB, Bella JN, Palmieri V,
et al
. Left ventricular systolic
dysfunction in a biracial sample of hypertensive adults: the Hypertension
Genetic Epidemiology Network (HyperGEN) study.
Hypertension
2001;
38
(3):
417–423.
23. McDonagh TA, Morrison CE, Lawrence A,
et al
. Symptomatic and
asymptomatic left-ventricular systolic dysfunction in an urban popula-
tion.
Lancet
1997;
350
(9081):
829–833.
24. Ntusi NB, Mayosi BM. Epidemiology of heart failure in sub-Saharan
Africa.
Expert Rev Cardiovasc Ther
2009;
7
(2):
169–180.
25. Mayosi BM. Contemporary trends in the epidemiology and manage-
ment of cardiomyopathy and pericarditis in sub-Saharan Africa.
Heart
2007;
93
(10):
1176–1183.
26. Vaughan JP. A brief review of cardiovascular disease in Africa.
Trans R
Soc Trop Med Hyg
1977;
71
(3):
226–231.
27. Rodeheffer RJ, Jacobsen SJ, Gersh BJ,
et al
. The incidence and preva-
lence of congestive heart failure in Rochester, Minnesota.
Mayo Clin
Proc
1993;
68
(12):
1143–1150.
28. Gillum RF. Epidemiology of heart failure in the United States.
Am
Heart J
1993;
126
(4):
1042–1047.
29. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression
from hypertension to congestive heart failure.
J A Med Assoc
1996;
275
(20): 1557–1562.
30. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prog-
nosis of diastolic heart failure: an epidemiologic perspective.
J Am Coll
Cardiol
1995;
26
(7):
1565–1574.
31. Adebiyi AA, Aje A, Ogah OS, Ojji DB, Oladapo OO, Falase AO. Left
ventricular diastolic function parameters in hypertensives.
J Natl Med
Assoc
2005;
97
(1): 41–45.
32. Zamora E, Lupon J, Lopez-Ayerbe J,
et al
. [Left atrium diameter: a
simple echocardiographic parameter with high prognostic value in heart
failure].
Med Clin (Barc)
2007;
129
(12):
441–445.
33. Spevack DM, Blum L, Malhotra D,
et al
. Ratio of left atrial to left
ventricular size: an anatomical marker of the diastolic left ventricular
pressure-volume relationship.
Echocardiography
2008;
25
(4): 366–373.
34. Chinali M, de Simone G, Liu JE,
et al
. Left atrial systolic force and
cardiac markers of preclinical disease in hypertensive patients: the
Hypertension Genetic Epidemiology Network (HyperGEN) Study.
Am
J Hypertens
2005;
18
(7):
899–905.
It's the
shell that
makes
safer.
R
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
